Patent Settlement Agreements
Patent Settlement Agreements
1. Introduction
A Patent Settlement Agreement (PSA) is an agreement between a patent holder and a potential infringer to resolve disputes outside court. These disputes usually involve patent infringement claims, particularly in the pharmaceutical sector.
Patent settlements are important because litigation is:
Expensive
Time-consuming
Uncertain in outcome
However, patent settlements can raise antitrust concerns if they delay the entry of generic drugs, affecting public access to affordable medicines.
2. Types of Patent Settlement Agreements
Traditional Settlement (No-Challenge Settlement)
The generic agrees not to challenge the patent.
The innovator may pay the generic company (“reverse payment”) to delay market entry.
Licensing Settlement
The parties agree on a license, allowing the generic to enter the market after a certain period.
Market-Splitting Settlement
The patent holder and the generic divide markets or agree on staggered entry.
Co-promotion or Supply Agreements
The generic company may help sell the innovator’s product or get a share of profits.
3. Legal Issues
Patent settlements often raise antitrust and competition law concerns, particularly:
“Pay-for-delay” settlements: Where the patent holder pays a generic to delay entry.
Whether settlements violate the Competition Act (India) or Sherman Act (US).
Balancing patent rights with public interest in affordable medicines.
4. Case Laws on Patent Settlement Agreements
Here are seven important cases, explained in detail:
Case 1: FTC v. Actavis, Inc. (2013) – USA
Facts:
Actavis, a generic company, settled with Solvay over the drug AndroGel, used to treat low testosterone.
Solvay paid Actavis to delay entering the market.
Legal Issue:
Whether “reverse payment” settlements violate the Sherman Antitrust Act.
Decision:
U.S. Supreme Court held: Not automatically legal.
Courts must evaluate whether the payment unreasonably restrains trade.
Reasoning:
Payments delaying generics harm consumers and competition.
Patent rights don’t give blanket immunity against antitrust scrutiny.
Significance:
Established the “rule of reason” test for reverse payment settlements.
Encouraged careful assessment of patent settlements in the pharma sector.
Case 2: In re: Ciprofloxacin Hydrochloride Antitrust Litigation (2003) – USA
Facts:
Bayer held the patent for Ciprofloxacin (Cipro).
Bayer entered a settlement with generic companies, limiting generic entry.
Legal Issue:
Whether settlements were anticompetitive.
Decision:
Court ruled settlements could be anti-competitive if they delayed generic entry.
Reasoning:
Payments to generics to delay market access harm consumers.
Settlements must be scrutinized under antitrust law.
Significance:
Early US case warning against pay-for-delay agreements.
Case 3: Novartis v. Union of India (2007–2013) – India
Facts:
Novartis patented Glivec, a cancer drug.
Novartis and a generic company reportedly negotiated settlements to limit generic entry in India.
Legal Issue:
Patent evergreening vs. delaying generics.
Decision:
Indian Patent Office rejected the patent under Section 3(d).
Court emphasized affordable access to life-saving drugs.
Significance:
Even settlements cannot override public health concerns.
Highlights India’s strong stance on preventing abuse of patent rights to block generics.
Case 4: Warner-Lambert v. Apotex (2007) – USA / Canada
Facts:
Dispute over Lipitor (cholesterol drug).
Warner-Lambert settled with Apotex, granting a license for later generic entry.
Legal Issue:
Whether settlement was lawful or anti-competitive.
Decision:
Settlement upheld because it included a valid license and was not a “reverse payment.”
Significance:
Shows settlements can be structured legally with a license to balance patent rights and competition.
Case 5: Pfizer v. Apotex (2012) – Canada
Facts:
Dispute over Pfizer’s Sutent (cancer drug).
Settlement included delayed generic entry but no payment.
Legal Issue:
Whether a delayed entry settlement without payment violated competition law.
Decision:
Court found the settlement permissible, unlike pay-for-delay cases in the U.S.
Significance:
Demonstrates jurisdictional differences: Canada allows delay settlements without payment, while U.S. courts scrutinize them heavily.
Case 6: Roche v. Cipla (2009) – India
Facts:
Roche challenged Cipla over a patent for Erlotinib.
Parties tried to negotiate a settlement for generic sale.
Decision:
Courts emphasized public interest over private settlements.
No injunction was granted to prevent generic sale.
Significance:
In India, settlements cannot override access to essential medicines.
Case 7: Bristol-Myers Squibb v. Teva (2005) – USA
Facts:
Bristol-Myers Squibb settled patent disputes over Plavix with Teva.
Settlement included a delayed market entry for the generic.
Legal Issue:
Reverse payment? Antitrust violation?
Decision:
Courts applied FTC v. Actavis reasoning.
Settlement was potentially anti-competitive but required further analysis under the rule of reason.
Significance:
Reinforced the principle: settlements delaying generics must be carefully evaluated.
5. Key Takeaways
Patent settlement agreements resolve disputes but can affect public health if they delay generics.
Pay-for-delay settlements are closely scrutinized under antitrust law (U.S.), but not all settlements are illegal.
Courts distinguish between:
Reverse payments (likely anti-competitive)
Licensing agreements or delayed entry without payment (may be legal)
In India, public health and access to essential medicines override private settlement agreements.
International frameworks (TRIPS, Doha Declaration) do not prevent governments from challenging settlements that limit access to medicine.
RELATED Blog
comments